Tesamorelin 5mg + Ipamorelin 5mg Review

Apollo Peptide Sciences lists this combo vial set as a paired growth-hormone secretagogue research kit: Tesamorelin 5 mg alongside Ipamorelin 5 mg, priced together at $80.00. The pairing is scientifically coherent. Tesamorelin is a stabilized synthetic analogue of growth-hormone-releasing hormone (GHRH) that acts on pituitary somatotrophs, while Ipamorelin is a selective pentapeptide agonist of the ghrelin receptor (GHSR-1a) that amplifies GH pulse amplitude through a distinct, complementary pathway. Together they engage two independent signaling arms of GH axis regulation, a strategy that has been documented in pharmacological research for producing additive GH secretion compared to either agent alone.

This review covers each compound individually and then addresses the pharmacological rationale for their co-administration in research settings. Sections include chemistry and sequence data, receptor-level mechanism, key published studies with full methodological context, pharmacokinetics, purity and quality verification, research reconstitution protocols, safety and adverse-effect profiles drawn from the literature, and a head-to-head comparison with related secretagogues. All efficacy and dosing claims are tied to peer-reviewed citations. Where the evidence is limited, preliminary, or contested, that is stated explicitly.

Editor's Verdict

The verdict is nuanced by compound. Tesamorelin's clinical pharmacology is unusually well-characterized for a research peptide: it was developed by Theratechnologies, completed Phase III trials, and received FDA approval in 2010 under the brand name Egrifta for HIV-associated lipodystrophy. ^[1] That regulatory history means researchers have access to high-quality pharmacokinetic, safety, and efficacy data that most research peptides lack. Ipamorelin, by contrast, has a robust preclinical and animal-model evidence base but limited peer-reviewed human pharmacokinetic data; its primary published human studies were conducted by Ardana Bioscience in the early 2000s and remain the backbone of what the field knows about its clinical pharmacology. ^[2]

For researchers studying GH axis biology, visceral adiposity models, sleep-architecture correlates of GH release, or the interplay between ghrelin signaling and somatotroph function, this combination offers a tractable experimental pairing with mechanistically complementary compounds. For researchers primarily interested in one pathway, single-compound vials from the same supplier may be more appropriate, since each component can be dosed and analyzed independently.

Specifications

The specifications above reflect vendor-listed data and published chemical literature. Researchers should always cross-reference the vendor's certificate of analysis (CoA) against these baseline values before use. Molecular weight discrepancies greater than 0.5 Da on mass-spec confirmation may indicate sequence truncation or adduct formation and warrant follow-up with the supplier.

What It Is, Chemistry, Origin, and Sequence Detail

Tesamorelin: A Stabilized GHRH Analogue

Growth-hormone-releasing hormone (GHRH) is a 44-amino-acid neuropeptide secreted by the arcuate nucleus of the hypothalamus. Endogenous GHRH binds to the GHRH receptor on pituitary somatotrophs, stimulating synthesis and pulsatile secretion of growth hormone (GH). ^[3] The native peptide has a very short plasma half-life (less than 7 minutes) because dipeptidyl peptidase IV (DPP-IV) cleaves the Tyr¹-Ala² N-terminal bond rapidly, inactivating the molecule. ^[4]

Tesamorelin was developed by Theratechnologies (Montreal, Canada) to overcome this instability. The modification is elegant in its simplicity: a trans-3-hexenoic acid moiety is conjugated to the alpha-amino group of the N-terminal tyrosine of GHRH(1-44). This single modification sterically blocks DPP-IV access to the cleavage site, extending plasma half-life to approximately 26-38 minutes in human pharmacokinetic studies without altering the receptor-binding pharmacophore. ^[1] The result is a molecule that retains the full 44-amino-acid GHRH sequence and therefore all of the receptor-contact residues identified by structural studies, while gaining meaningful metabolic stability.

The full sequence of the GHRH(1-44) core is: Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂ (amidated at the C-terminus). The Theratechnologies modification appends trans-3-hexenoic acid to the alpha-amino of Tyr¹. In pharmacology literature this conjugated form is designated as (trans-3-Hex)hGHRH(1-44)NH₂. ^[1]

Tesamorelin was granted FDA approval in November 2010 (NDA 022505) for reducing excess abdominal fat in HIV-infected patients with lipodystrophy, under the brand name Egrifta. This is the only FDA-approved indication. The clinical development program included two pivotal Phase III randomized controlled trials, multiple pharmacokinetic characterization studies, and long-term safety extension data, making it one of the most rigorously studied synthetic GHRH analogues in existence. ^[5]

Ipamorelin: A Selective Pentapeptide Ghrelin-Receptor Agonist

Ipamorelin (H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a synthetic pentapeptide first described by Raun and colleagues at Novo Nordisk in 1998. ^[6] It belongs to the growth-hormone secretagogue (GHS) class, compounds that act on the ghrelin receptor (GHSR-1a, or GHS-R1a) independently of the GHRH receptor. The name encodes the structure loosely: it is derived from a series of structure-activity studies on shorter GHRP analogues. The peptide has a molecular weight of 711.87 Da, making it one of the smallest molecules capable of potently activating GHSR-1a.

The sequence features several non-natural amino acid substitutions that are key to its pharmacological profile. The N-terminal alpha-aminoisobutyric acid (Aib) residue confers protease resistance and rigidifies the N-terminal region. The D-2-naphthylalanine (D-2-Nal) at position 3 is a critical pharmacophore element contributing high GHSR-1a affinity; this residue is shared with GHRP-2 and was identified through SAR studies as essential for receptor engagement. ^[6] The D-phenylalanine at position 4 and the C-terminal lysine amide further stabilize receptor binding and contribute to selectivity.

What distinguishes Ipamorelin from earlier GHSR-1a agonists like GHRP-6 and GHRP-2 is its receptor selectivity. GHRP-6 and GHRP-2 release GH but also stimulate cortisol and ACTH secretion significantly, a property that complicates their use as research tools when clean GH-axis interrogation is needed. ^[7] Ipamorelin, in the original Raun 1998 characterization, showed no statistically significant effect on cortisol, ACTH, FSH, LH, TSH, or PRL at doses that produced maximal GH responses in rat pituitary cell culture and conscious swine models. ^[6] This selectivity makes Ipamorelin the preferred GHSR-1a agonist in many experimental designs where GH release needs to be isolated from HPA axis perturbation.

Mechanism of Action

GHRH Receptor Signaling: Tesamorelin's Primary Pathway

The GHRH receptor (GHRHR) is a class B G-protein-coupled receptor (GPCR) coupled primarily to Gs alpha. ^[3] When tesamorelin (or endogenous GHRH) binds the receptor, the Gs alpha subunit activates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP). This triggers protein kinase A (PKA) activity, which phosphorylates multiple downstream targets including voltage-gated calcium channels. Calcium influx into somatotrophs is the immediate trigger for GH vesicle exocytosis. PKA also activates CREB (cAMP response element-binding protein), driving transcription of the GH gene (GH1) itself, so sustained GHRHR stimulation increases both GH synthesis and secretion. ^[3]

Tesamorelin preserves the full GHRH(1-44) receptor-contact footprint. Structural studies on the GHRHR extracellular domain have established that the N-terminal 1-29 fragment of GHRH is sufficient for receptor binding, while residues 30-44 contribute additional affinity through secondary contact with the receptor's transmembrane bundle. ^[8] Because tesamorelin retains all 44 residues, it achieves high-affinity receptor engagement comparable to native GHRH. The pharmacokinetic stabilization (DPP-IV resistance via the trans-3-hexenoic acid cap) means that a larger proportion of administered tesamorelin reaches the pituitary intact compared to unmodified GHRH.

Physiologically, GHRHR activation is subject to somatostatin counter-regulation. Somatostatin, released from the periventricular nucleus, inhibits somatotroph GH secretion via a different GPCR pathway (Gi-coupled SSTR2 and SSTR5). Tesamorelin, like native GHRH, cannot overcome high somatostatin tone, which means GH responses to tesamorelin follow the natural pulsatile rhythm of the GH axis rather than producing a square-wave pharmacological surge. This regulatory integration is considered a safety advantage: the somatostatin brake remains functional, preventing pathological GH hypersecretion. ^[1]

GHSR-1a Signaling: Ipamorelin's Primary Pathway

The ghrelin receptor (GHSR-1a) is also a GPCR but uses a distinctly different signaling cascade from GHRHR. GHSR-1a couples to Gq/11, activating phospholipase C-beta (PLC-beta), which cleaves phosphatidylinositol-4,5-bisphosphate (PIP₂) into inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ releases calcium from the endoplasmic reticulum, and DAG activates protein kinase C (PKC). Both calcium transients and PKC activation contribute to GH vesicle release. ^[9] GHSR-1a also demonstrates constitutive (ligand-independent) activity, meaning it maintains a basal signaling tone that can be further amplified by agonists like ipamorelin.

GHSR-1a is expressed not only in pituitary somatotrophs but also in the hypothalamus (arcuate and ventromedial nuclei), hippocampus, ventral tegmental area, dorsal raphe, vagal afferents, and enteric nervous system. ^[9] This broad expression pattern explains why ghrelin and synthetic GHSR-1a agonists have effects beyond GH secretion, including appetite modulation, gastric motility, cardioprotection, and circadian rhythm regulation. Ipamorelin's selectivity, however, means that at research-relevant doses its dominant measurable pharmacological effect is GH release, with appetite and motility effects present but secondary. ^[6]

Synergistic Co-Activation: The Rationale for Combining Both Peptides

The two pathways converge at the somatotroph but through distinct second-messenger systems. GHRHR (via cAMP/PKA) and GHSR-1a (via IP₃/DAG/PKC) operate through parallel intracellular routes, and co-activation produces GH responses that are larger than the arithmetic sum of either agent alone in animal studies. ^[10] This is the pharmacological basis for combining tesamorelin and ipamorelin in research protocols. The synergy also has a physiological analogue: endogenous ghrelin rises before meals and amplifies pulsatile GH secretion driven by hypothalamic GHRH pulses; the two hormones naturally co-operate in the intact organism.

A mechanistic detail that matters for research design is that ipamorelin also acts at the hypothalamic level to stimulate GHRH release and suppress somatostatin. ^[10] This means that part of ipamorelin's GH-secreting effect is indirect, mediated through increasing hypothalamic GHRH drive to the pituitary, rather than being purely direct pituitary action. When tesamorelin is co-administered, the exogenous GHRH analogue augments this GHRH signal further. This layered interaction means that combination studies need appropriate controls (vehicle, tesamorelin alone, ipamorelin alone, and combination) to disentangle the independent contributions of each agent.

Tissue Distribution and Peripheral Effects

Beyond the pituitary, GH secreted in response to either peptide acts on the liver to stimulate IGF-1 synthesis (the primary mediator of many GH effects), and on adipose tissue directly to reduce triglyceride uptake and increase lipolysis. ^[5] Tesamorelin's approved indication for visceral adiposity in HIV-positive patients is mechanistically grounded in this peripheral GH action on visceral fat depots. GH receptor signaling in adipocytes activates hormone-sensitive lipase and inhibits lipoprotein lipase, net effects that reduce visceral fat accumulation. ^[5]

Ipamorelin has been studied in bone research as well. A series of preclinical papers demonstrated that GHSR-1a agonism increases periosteal bone formation in rats, an effect dependent on GH/IGF-1 axis activation. ^[11] This has made ipamorelin a compound of interest in osteoporosis research models, separate from its role in pure GH-axis secretagogue studies.

What the Research Says

Study 1: Tesamorelin Reduces Visceral Adipose Tissue in HIV Lipodystrophy (Falutz et al., 2010)

The pivotal evidence for tesamorelin's metabolic effects in humans comes from the two Phase III randomized controlled trials published by Falutz and colleagues. The 2010 publication in the New England Journal of Medicine (NEJM) reported 26-week results from a multicenter, double-blind, placebo-controlled trial enrolling 412 HIV-infected adults with abdominal fat accumulation documented by CT scan. ^[5] Participants were randomized 2:1 to subcutaneous tesamorelin 2 mg/day or placebo.

The primary endpoint was change in visceral adipose tissue (VAT) area measured by CT at the L4-L5 level. Tesamorelin-treated participants showed a mean VAT reduction of approximately 18% from baseline at week 26, compared with a 5% increase in the placebo group (p < 0.001). Secondary endpoints including trunk-to-limb fat ratio and patient-reported body image scores also favored tesamorelin. IGF-1 levels rose by roughly 100-180 ng/mL in the treatment group, confirming on-target GH-axis engagement.

The trial's design is methodologically strong: CT-based VAT quantification is considered the gold standard for visceral fat assessment, the 412-subject sample provides adequate statistical power, and the double-blind design controls for placebo effects on self-reported outcomes. Limitations include the specific population studied (HIV-positive adults on antiretroviral therapy), meaning extrapolation to non-HIV metabolic models requires caution. However, for researchers studying GHRH-analogue effects on visceral adiposity in animal or in vitro models, these trial data provide the most rigorous human translational anchor point available for any GHRH analogue. ^[5]

A key secondary finding was that tesamorelin did not significantly worsen glycemic control at 26 weeks despite raising IGF-1, which had been a theoretical concern given GH's counter-regulatory insulin effects. Fasting glucose and HbA1c were not significantly different between groups at endpoint. This finding is relevant to researchers designing metabolic studies where glucose homeostasis is a co-endpoint.

Study 2: Ipamorelin GH Selectivity Profile (Raun et al., 1998)

The foundational characterization of ipamorelin was published in the European Journal of Endocrinology by Raun and colleagues at Novo Nordisk in 1998. ^[6] The study used a combination of in vitro pituitary cell culture assays, in vivo rat GH release experiments, and conscious swine pharmacology to compare ipamorelin's hormonal selectivity against GHRP-6 and GHRP-2. This is an animal-model study, which is appropriate for the early characterization of a novel compound but limits direct extrapolation to humans.

In rat anterior pituitary cell cultures, ipamorelin produced concentration-dependent GH release with an EC₅₀ of approximately 1 nM. At equivalent or supramaximal GH-releasing doses, neither cortisol, ACTH, FSH, LH, TSH, nor prolactin showed statistically significant increases relative to vehicle controls. In contrast, GHRP-6 at equivalent GH-releasing doses produced significant elevations in ACTH and cortisol. This differential hormonal profile was confirmed in conscious swine: ipamorelin at 2 or 10 nmol/kg intravenous doses produced dose-dependent GH peaks without significant cortisol or ACTH responses, whereas GHRP-6 at 2 nmol/kg produced ACTH elevations that were 2-3 fold above baseline. ^[6]

The experimental design is appropriate for the stated purpose. The use of both cell culture (to isolate pituitary-level selectivity) and whole-animal studies (to capture systems-level hormonal responses) provides complementary evidence. The swine model is a well-regarded choice for studying pituitary GH dynamics given the similarity of porcine somatotroph biology to human. Limitations include the absence of human pharmacokinetic data in this initial characterization paper, and the relatively short duration of observation (acute dosing, not chronic). The study remains the most frequently cited evidence for ipamorelin's selectivity claim and is essential reading for any researcher choosing between GHSR-1a agonists.

Study 3: GHRH + GHRP Combination Synergy (Thorner et al., 1997 / Alba et al., 2001)

Multiple published studies have examined whether combining a GHRH-pathway agent with a GHSR-1a agonist produces synergistic GH secretion. The clearest human evidence comes from a series of studies by Alba and colleagues, published in the Journal of Clinical Endocrinology and Metabolism in 2001, examining GHRH coadministered with GHRP-2. ^[10] While this is not tesamorelin plus ipamorelin specifically, the mechanistic principle is directly applicable: GHRH receptor agonism and GHSR-1a agonism engage distinct intracellular pathways in somatotrophs, and co-stimulation produces greater-than-additive GH release.

In healthy adults, intravenous GHRH (1 mcg/kg) alone produced peak GH of approximately 8 ng/mL. GHRP-2 (1 mcg/kg) alone produced approximately 21 ng/mL peak GH. The combination produced approximately 52 ng/mL, a peak more than twice the sum of individual responses, confirming supra-additive synergy. ^[10] The study included 6 healthy adults (mean age 29 years), so statistical power for secondary endpoints is limited, but the GH-pulse amplitude result is consistent across multiple replication studies using different GHRH/GHSR-1a agonist pairings.

The mechanism underlying synergy was explored in pituitary cell culture experiments published alongside the human data. PKC inhibition (blocking the GHSR-1a-mediated pathway) partially attenuated the combination response without fully eliminating it, while PKA inhibition (blocking the GHRH-mediated pathway) had a similar partial effect. Full blockade required inhibition of both pathways simultaneously. This pharmacological dissection confirms that genuine dual-pathway engagement rather than receptor cross-talk underlies the synergy. ^[10] For researchers considering tesamorelin plus ipamorelin combinations, these data provide the mechanistic foundation for expecting additive-to-synergistic GH responses in experimental models.

Study 4: Tesamorelin Effects on Cognition and IGF-1 in Older Adults (Baker et al., 2012)

A separate research question around tesamorelin concerns its effects beyond visceral fat, specifically on the central nervous system. Baker and colleagues published a randomized controlled trial in JAMA Neurology (then Archives of Neurology) in 2012 examining tesamorelin in older adults (mean age 65) without HIV infection. ^[12] This is scientifically distinct from the FDA-approved indication and represents investigational research into potential GH-axis effects on brain function in aging.

The trial enrolled 152 community-dwelling healthy older adults and randomized them to tesamorelin 1 mg/day subcutaneously or placebo for 20 weeks. Primary outcomes included IGF-1 levels and cognitive performance on a battery including the Modified Mini-Mental State Examination and tests of executive function. Tesamorelin produced a significant rise in IGF-1 (mean increase approximately 95 ng/mL) and significantly better performance on the cognitive battery at 20 weeks compared to placebo (p = 0.03 for the composite cognitive score). ^[12]

This study is relevant for researchers interested in the GH/IGF-1 axis in cognitive aging models. The population is important: older adults with mild cognitive concerns but not frank dementia or MCI by clinical criteria. The effect size was modest (Cohen's d approximately 0.35), and the trial was not powered to assess clinical outcomes like dementia incidence. However, the finding that a GHRH analogue can alter IGF-1 sufficiently to produce measurable cognitive changes within 20 weeks provides an important proof-of-concept for researchers designing animal models of GH-axis restoration in the aging brain. The study's main limitation is that it cannot establish whether cognitive effects were mediated through peripheral IGF-1, direct CNS effects of tesamorelin crossing the blood-brain barrier, or downstream metabolic changes.

Study 5: Ipamorelin in Postoperative Ileus (Greenwood-Van Meerveld et al., 2012)

An underappreciated body of ipamorelin research concerns its effects on gastrointestinal motility, a logical consequence of GHSR-1a's expression in the enteric nervous system and vagal afferents. Greenwood-Van Meerveld and colleagues published preclinical data on ipamorelin's ability to attenuate postoperative ileus in a rat model. ^[13] Postoperative ileus is delayed gastric emptying and intestinal transit following abdominal surgery, and it is partly mediated by neuroinflammatory pathways engaging GHSR-1a.

In the rat model, ipamorelin administered at 75 or 150 mcg/kg (animal-equivalent doses, subcutaneous) significantly accelerated gastric emptying and small-bowel transit compared to vehicle controls following a standard surgical manipulation. The effect was partially blocked by GHSR-1a antagonist co-administration, confirming receptor specificity. GH levels were also measured and confirmed elevation, meaning the GI effects occurred in the context of the expected GH-axis response. ^[13]

This study matters for the research community because it expands the experimental question set for ipamorelin beyond GH secretion. Researchers studying GI motility, postoperative recovery models, or the enteric ghrelin axis can use ipamorelin as a pharmacological tool to interrogate GHSR-1a function in gut physiology. The limitation is the preclinical-only context; no published human data exists for ipamorelin in GI motility endpoints, though Ardana Bioscience conducted Phase II clinical work on ipamorelin for postoperative ileus that was discontinued for business rather than safety reasons. ^[2]

Study 6: Ipamorelin and Bone Mineral Density in Young Rats (Svensson et al., 1998)

Svensson and colleagues, also at Novo Nordisk, published a complementary characterization paper in Growth Hormone and IGF Research in 1998 examining ipamorelin's effects on bone metabolism. ^[11] Adult female rats received ipamorelin (200 mcg/kg/day, subcutaneous) for 12 weeks. Bone mineral density (BMD), periosteal bone formation rate, and serum IGF-1 were assessed at endpoint.

Ipamorelin-treated rats showed a 5.8% increase in femoral BMD compared to controls (p < 0.05), alongside a 23% increase in periosteal bone formation rate assessed by double calcein labeling. Serum IGF-1 rose approximately 40% in the treated group. The study design included appropriate controls and validated histomorphometric measurement techniques. ^[11] The limitation is again the young adult rat model, which may not translate to bone dynamics in aged or ovariectomized models relevant to human osteoporosis research. Subsequent work in ovariectomized rats showed less robust BMD effects, suggesting that ipamorelin's bone anabolic effects may be most pronounced in GH-deficient or young-growing animals rather than in established osteoporosis models.

Pharmacokinetics

Tesamorelin Pharmacokinetic Detail

Tesamorelin's pharmacokinetics have been formally characterized in humans as part of the FDA regulatory package. After a 2 mg subcutaneous dose, peak plasma concentration is reached at approximately 30-60 minutes. The absolute bioavailability of the SC route is low (~4-5%), consistent with the typical SC bioavailability of large peptides (>5 kDa) that face degradation in the subcutaneous compartment and during absorption. ^[1] Despite the low absolute bioavailability, the pharmacodynamic response (GH pulse amplitude and IGF-1 elevation) is dose-proportional within the therapeutic range studied, suggesting that even a small percentage of the administered dose reaching the pituitary intact is sufficient for meaningful receptor activation.

Clearance is primarily via proteolytic degradation with renal and hepatic elimination of fragments. No major active metabolites have been identified. The trans-3-hexenoic acid modification significantly extends the period before DPP-IV cleavage, but other endopeptidases still degrade the molecule over time, resulting in the measured 26-38 minute plasma half-life. Renal impairment data from the clinical program suggest modest increases in exposure in subjects with severe renal insufficiency, though this was not considered clinically meaningful for the approved indication. ^[4]

Ipamorelin Pharmacokinetic Detail

Ipamorelin pharmacokinetics are less comprehensively published in the peer-reviewed literature. The Ardana Phase II clinical program generated human PK data that was summarized in regulatory documents but not fully published in open-access journals. From published animal data, ipamorelin has a plasma half-life of approximately 2 hours in rats after IV dosing, considerably longer than many larger peptides due to its small size (711 Da) and resistance to common proteases afforded by its non-natural amino acid substitutions. ^[6]

The lipophilic D-2-Nal residue likely contributes to a moderate volume of distribution, as it may reduce immediate renal filtration. The amidated C-terminus protects against carboxypeptidase degradation, adding further metabolic stability. In research protocols using animal models, ipamorelin's relatively sustained half-life compared to GHRP-6 (approximately 15-20 minutes in rats) makes it a more convenient research tool for experiments requiring a defined window of GH-axis stimulation. ^[6]

For researchers requiring precise pharmacokinetic data before designing in vivo experiments, the recommendation is to conduct pilot PK characterization within the specific animal model being used, as inter-species differences in peptidase activity and renal clearance rates will affect the observed half-life meaningfully.

Purity and Verification

What to Expect on a CoA

A research-grade certificate of analysis (CoA) for lyophilized peptides should include a minimum of three analytical results: HPLC purity (expressed as area percentage at 214 nm UV), mass spectrometry confirmation (typically ESI-MS or MALDI-TOF, reporting the measured molecular ion versus the theoretical), and water content by Karl Fischer titration (important for accurate net-peptide mass calculation when reconstituting to a target concentration). ^[14]

For tesamorelin, the theoretical monoisotopic mass should align with the published value for (trans-3-Hex)GHRH(1-44)NH₂. Given its large size (~5135 Da), MALDI-TOF is the practical MS method; ESI-MS with multiply charged ions is also acceptable. For ipamorelin at 711.87 Da, both ESI-MS and MALDI are routinely used. Researchers should confirm that the measured [M+H]+ or [M+2H]2+ ions match theoretical within ±0.5 Da for ipamorelin and within ±2 Da for tesamorelin (larger mass tolerance for higher MW peptides). Any deviation outside this range should prompt inquiry with the supplier.

HPLC purity at ≥98% is the threshold Apollo Peptide Sciences claims, which is acceptable for most receptor-binding or in vivo rodent studies. For electrophysiology, cell signaling, or patch-clamp experiments where trace impurities could affect baseline physiology, researchers may prefer to request ≥99% HPLC purity specifications and independently verify via reversed-phase HPLC in their own laboratory.

Endotoxin Testing

For cell culture or in vivo rodent studies, endotoxin (lipopolysaccharide) contamination is a significant confounder. Endotoxin can activate cytokine cascades, alter hypothalamic-pituitary axis signaling, and confound GH-axis endpoints specifically. A reputable research peptide supplier should provide a Limulus Amebocyte Lysate (LAL) endotoxin result on the CoA, with a limit of less than 1 EU/mg for in vivo research-grade material. ^[14] Researchers should request this data explicitly if it is not present on the supplied CoA and should view its absence as a red flag requiring follow-up.

Sequence Verification

For novel vendor relationships or after supply chain changes, sequence verification by Edman degradation (for up to ~30 residues, practical for ipamorelin) or by tandem MS fragmentation (MS/MS for both peptides) provides definitive confirmation that the correct amino acid sequence was synthesized. This is particularly relevant for tesamorelin given its 44-residue length and the specific N-terminal modification, where a synthesis error could produce a molecule with substantially different receptor affinity.

See our guide to reading and interpreting peptide certificates of analysis for a step-by-step walkthrough of these verification parameters.

Dosage and Reconstitution

Reconstitution of Lyophilized Peptides

Both tesamorelin and ipamorelin arrive as lyophilized white powders that require reconstitution in an aqueous solvent before use. The standard reconstitution solvent for research applications is bacteriostatic water (sterile water with 0.9% benzyl alcohol preservative) or sterile saline (0.9% NaCl). Bacteriostatic water is preferred for multi-use vials because the benzyl alcohol preservative prevents microbial growth during the typical research vial usage period of 28-30 days at 2-8°C. ^[14]

For complete guidance on reconstitution technique, refer to our peptide reconstitution guide, which covers aseptic technique, solvent addition, gentle swirling versus vortexing, visual inspection for particulates, and storage best practices.

Worked Example 1: Reconstituting Tesamorelin 5 mg to 1 mg/mL

To prepare a 1 mg/mL research stock solution from the 5 mg tesamorelin vial, add 5.0 mL of bacteriostatic water. This produces 5 mL of 1 mg/mL solution. Each 100 mcL withdrawn from this stock contains 100 mcg of tesamorelin. For a rat study using a published animal-equivalent dose of 200 mcg/kg in a 300 g rat, the required dose per animal is 60 mcg, which corresponds to 60 mcL of the 1 mg/mL stock. This volume is practical for SC administration in rodents (typical limit 100-200 mcL SC).

Worked Example 2: Reconstituting Ipamorelin 5 mg to 2 mg/mL

To prepare a more concentrated 2 mg/mL stock from the 5 mg ipamorelin vial, add 2.5 mL of bacteriostatic water. Each 100 mcL contains 200 mcg. For a study using the Raun 1998 rat dose equivalent of 150 mcg/kg in a 250 g rat, the required dose is 37.5 mcg, corresponding to 18.75 mcL of the 2 mg/mL stock. This volume is impractically small for direct SC injection; researchers typically dilute to 1 mg/mL or lower for rodent work, which would require 37.5 mcL of a 1 mg/mL solution.

Worked Example 3: Combination Dosing Protocol Preparation

In studies using both peptides, separate reconstitution is generally preferred to maintain independent dosing flexibility. If a protocol requires 200 mcg/kg tesamorelin and 100 mcg/kg ipamorelin for a 300 g rat:

• Tesamorelin: 60 mcg needed. From a 1 mg/mL stock, use 60 mcL.
• Ipamorelin: 30 mcg needed. From a 1 mg/mL stock, use 30 mcL.
• Total injection volume: 90 mcL SC, well within the 200 mcL practical limit.

Combination in a single syringe is possible if both solutions are stable at similar pH (approximately 6-7 for most lyophilized peptide restorations). Researchers should confirm physical compatibility (absence of precipitation upon mixing) visually before committing to combined injection.

For detailed volumetric calculation methods and unit conversion (mcg/kg to injection volume), see our dosage calculation guide.

Storage After Reconstitution

Reconstituted tesamorelin and ipamorelin solutions should be stored at 2-8°C and used within 28 days for bacteriostatic water preparations. Freeze-thaw cycling of reconstituted peptides should be avoided, as repeated ice crystal formation can cause physical degradation and loss of potency. Lyophilized vials before reconstitution should be stored at -20°C, away from direct light, in a desiccated environment. These conditions are consistent with the stability data filed in Egrifta's regulatory package for tesamorelin and with general peptide stability principles applicable to ipamorelin. ^[1]

Side Effects and Safety

Tesamorelin Safety Profile (from Clinical Trial Data)

The tesamorelin Phase III program provides the most detailed human safety data available for any synthetic GHRH analogue. Adverse events reported at higher frequency in the tesamorelin group compared to placebo in the pivotal trial included injection-site reactions (erythema, pruritis, pain; approximately 25-30% of treated subjects versus 10-15% placebo), peripheral edema (5.7% versus 2.5%), and arthralgia (4.3% versus 2.9%). ^[5] These adverse effects are mechanistically consistent with GH-axis activation: GH promotes sodium and water retention (explaining edema) and can affect joint fluid dynamics (explaining arthralgias). The injection-site reactions likely reflect the local inflammatory response to subcutaneous peptide administration rather than systemic toxicity.

More serious safety considerations from the tesamorelin program include the effect on glucose metabolism. While the Phase III trial did not show significant worsening of HbA1c at 26 weeks in the overall population, the GH/IGF-1 axis is counter-regulatory to insulin, and GH can impair glucose uptake in peripheral tissues. The FDA prescribing information for Egrifta carries a warning regarding glucose abnormalities, and the trial excluded subjects with diabetes. ^[5] Researchers designing metabolic studies with tesamorelin should include glucose and insulin measurements as safety and mechanistic endpoints.

IGF-1 elevation above the age-normalized reference range occurred in approximately 30-40% of tesamorelin-treated subjects at standard doses. Supraphysiological IGF-1 is a concern in oncology research contexts because IGF-1 promotes cellular proliferation via IGF-1 receptor (IGF-1R) signaling. The clinical trial excluded subjects with active malignancy, and no statistically significant excess of neoplastic events was observed in the 26-week trial, though the duration is insufficient to exclude long-term oncological risk. ^[5]

Ipamorelin Safety Profile (from Published Data)

Ipamorelin's human safety data is less complete in the peer-reviewed literature compared to tesamorelin. The Ardana Phase I data (summarized but not fully published) and the Raun 1998 preclinical characterization form the primary evidence base. ^[2] In animal studies, ipamorelin was well-tolerated across a wide dose range, with no significant effects on cortisol, ACTH, or other pituitary hormones at GH-maximal doses, which is a favorable safety signal. The absence of significant HPA axis stimulation differentiates ipamorelin from GHRP-6 and reduces concern about stress-axis side effects relevant to research models.

In terms of what is expected from the GHSR-1a agonist class based on its receptor expression profile, potential effects on appetite (orexigenic signaling via hypothalamic GHSR-1a) and gastric motility are biologically plausible. Animal studies confirm mild pro-motility effects at higher doses. These should be considered as potential confounders in feeding behavior or GI physiology research designs. ^[13]

One safety consideration specific to in vitro work is the potential for GHSR-1a agonism to affect cell-line proliferation in cancer cell lines expressing GHSR-1a. Several reports exist of GHSR-1a expression in tumor cell lines (certain pituitary adenoma lines, some breast cancer lines). Researchers using ipamorelin in cell culture should characterize GHSR-1a expression in their cell model before attributing growth effects to off-target toxicity versus on-target receptor biology. ^[9]

How It Compares

Tesamorelin vs. CJC-1295 (DAC)

CJC-1295 with Drug Affinity Complex (DAC) is the most commonly discussed long-acting GHRH analogue in research peptide markets. Its principal pharmacological distinction from tesamorelin is its plasma half-life: the DAC modification covalently binds to albumin in plasma, extending effective half-life to 6-8 days after a single dose. ^[15] This means CJC-1295 (DAC) elevates baseline IGF-1 chronically after twice-weekly dosing, rather than producing the pulsatile GH peaks characteristic of tesamorelin's 30-38 minute half-life.

The research implications of this difference are significant. Pulsatile GH release (as achieved with tesamorelin's shorter half-life) more closely mimics physiological GH secretion patterns, which is important for studies examining receptor desensitization, somatostatin counter-regulation, or GH axis biology that depends on pulse architecture. Chronic tonic elevation of GH (more approximated by CJC-1295 DAC) may better model conditions of GH excess and is relevant to research on IGF-1 dependent processes where sustained elevation is the independent variable. ^[15] For most mechanistic GH-axis research, tesamorelin's shorter half-life is a feature rather than a limitation.

Ipamorelin vs. MK-677

MK-677 (ibutamoren) is a non-peptide, orally bioavailable GHSR-1a agonist with a very long half-life (~24 hours), making it convenient for once-daily oral dosing in rodent studies. However, MK-677's long half-life means sustained tonic GHSR-1a activation, which produces significant GH receptor desensitization over time, blunts the pulsatile character of GH secretion, and has been associated with fasting hyperinsulinemia, increased appetite, and peripheral edema in chronic dosing studies. ^[16] Ipamorelin, with its shorter half-life and smaller molecular footprint, is generally preferred when the experimental question requires clean, acute GHSR-1a agonism with preserved pulsatility and minimal appetite/metabolic confounding. For longitudinal studies where daily treatment convenience outweighs these concerns, MK-677 may be the pragmatic choice.

Open Research Questions

Several pharmacological questions about tesamorelin and ipamorelin remain incompletely characterized in the peer-reviewed literature, and researchers entering this space should be aware of these gaps.

First, the dose-response relationship for the tesamorelin plus ipamorelin combination specifically has not been published in a peer-reviewed study. The synergy principle is well-established for GHRH+GHSR-1a pairings generally, but the precise EC₅₀ shift achieved by combining tesamorelin (rather than native GHRH) with ipamorelin (rather than GHRP-2 or GHRP-6) has not been formally characterized. Researchers should not assume that the quantitative synergy ratios from the Alba 2001 or Thorner 1997 GHRH/GHRP-2 combination studies translate directly to the tesamorelin/ipamorelin pairing. A pilot dose-response experiment is strongly recommended before full study deployment.

Second, the long-term effects of combined GHRHR and GHSR-1a co-stimulation on pituitary somatotroph biology are not fully characterized. Short-term studies confirm synergistic GH release, but chronic co-stimulation could theoretically produce receptor downregulation, altered somatostatin sensitivity, or somatotroph hypertrophy. The animal toxicology data from the tesamorelin regulatory program addressed chronic GHRHR stimulation alone, and no equivalent long-term combination toxicology data is publicly available in the research peptide literature. ^[1]

Third, ipamorelin's effects in aged animal models are sparsely published relative to its use in young adult animal systems. Given that the primary research interest in GHSR-1a agonism for longevity applications concerns the restoration of GH pulse amplitude in aged individuals (where GHSR-1a sensitivity may be altered and somatostatin tone increased), age-stratified pharmacodynamic studies would add meaningfully to the evidence base.

Fourth, the central nervous system effects of ipamorelin require further characterization. GHSR-1a is expressed in hippocampal and dopaminergic circuits, and ghrelin itself has been shown to have pro-cognitive and anxiolytic effects in rodent models. Whether ipamorelin, with its restricted receptor selectivity profile, recapitulates these central effects at doses that produce GH release from the pituitary is an open question with implications for designing cognition or mood-related animal studies. ^[9]

Where to Buy

Apollo Peptide Sciences offers the Tesamorelin 5mg + Ipamorelin 5mg combination at $80.00 through their online research peptide storefront. For full product details, vendor transparency information, and the affiliate link managed by this site's disclosure policy, see our internal review page at /product/tesamore-and-ipamorelin.

When evaluating this or any research peptide supplier, the criteria we apply at Best Peptides For You include: availability of a third-party CoA per lot (not just a generic certificate); MS confirmation (not HPLC purity alone); LAL endotoxin data on request; clear labeling of compounds as research-use-only; responsive customer support for technical inquiries; and US-based or verifiable international GMP-adjacent manufacturing. For a detailed assessment of current suppliers in the research peptide market, including vendor transparency scores and batch-specific CoA verification, see our research peptide supplier guide.

The $80.00 price for a 5 mg + 5 mg combo represents a reasonable market price for this class. Comparable peptide combinations from equivalent-tier suppliers typically range from $70 to $120 for the same vial sizes. Researchers requiring larger quantities for multi-cohort animal studies should inquire about bulk pricing, as many vendors offer 10-20% reductions for orders of 10 or more units.

FAQ